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Summary
Lung transplantation is an established therapeutic option
for end-stage lung disease in selected patients. During the
last 30 years more than 34,000 transplantations have been
performed worldwide. Emphysema, pulmonary fibrosis,
cystic fibrosis and primary pulmonary hypertension are the
most common indications. This type of surgical treatment
is increasingly successful, with better early and late surviv-
al rates. However, lung transplantation is still hampered by
persisting problems such as donor organ shortage, primary
graft dysfunction, late graft dysfunction and morbidity re-
lated to long-term immunosuppression. The first lung
transplantation in Switzerland was performed the 10th
November 1992 at Zurich University Hospital. Since then
the lung transplant programme has progressively increased
its yearly transplant volume. Since the beginning of our
lung transplantation programme, overall patient survival
has increased steadily and has been at benchmark levels
since the year 2000. The most important factors influencing
this result are presumably good teamwork among all in-
volved specialists, improved surgical techniques, and close
and long-term patient follow-up by the transplant pulmono-
logists. In this paper we present our programme structure,
managing strategies for some specific problems and out-
come after lung transplantation. The results presented here
are from recipients who underwent lung transplantation up
to the end of 2011.
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Programme structure
A potential lung transplant candidate is seen at least three
times as an outpatient by the pulmonologists in order to as-
sess urgency of evaluation and possible contraindications.
Information concerning evaluation and follow-up after
lung transplantation is provided. Pretransplant work-up is
done during a hospitalisation on the pulmonary ward. Dur-
ing this evaluation period, members of the multidisciplin-
ary team see the patient and document their decision in
writing before attending the interdisciplinary colloquium
which evaluates the listing of the patient. The evaluation
team includes dedicated lung transplant specialists from
thoracic (cardiac) surgery, pulmonary medicine, psychiatry,
endocrinology, cardiology, anaesthesia, physiotherapy, nu-
trition, infectious diseases and surgical intensive care, and
transplant coordinators. The core transplant care team, con-
sisting of thoracic surgeons and pulmonologists, meets
every week to discuss the recently transplanted patients
who are on the ward, and the current condition of the pa-
tients on the waiting list.
In the early postoperative phase, patients are managed by
the surgical intensive care members on the intensive care
unit (ICU), with the main contribution coming from
thoracic surgery and pulmonary medicine specialists. After
transfer to the ward, recipients are followed up by the
thoracic surgery team, with daily visits from a pulmono-
logist. After discharge, the transplanted patients are fol-
lowed up closely for life by transplant pulmonologists. In
the event of hospital readmission for any reason, the patient
is admitted at our university hospital to the pulmonary ward
or other wards under the supervision of pulmonologists.
Patient evaluation and selection criteria
After a referral for lung transplantation, we provide a rapid
and efficient work-up procedure for the potential candidate.
This work-up includes, but is not limited to, standard labor-
atory tests, chest X-ray, high resolution computed axial
tomography scanning, abdominal ultrasound, bone densit-
ometry, mammography, pulmonary function tests, arterial
blood gas analysis, 6-minute walking test, electrocardi-
ogram, echocardiography, left and sometimes right heart
catheterisation, lung perfusion scan, and expert evaluation
by specialists in thoracic surgery, pulmonology, gastroen-
terology, otorhinolaryngology, cardiology, ophthalmology,
endocrinology, angiology, dermatology, psychiatry, anaes-
thesia and nutrition.
For patient selection our programme follows the widely
accepted criteria established by the International Society
for Heart and Lung Transplantation (ISHLT) [1]. The list
of absolute contraindications is given in box 1. Owing to
the increased experience at our centre, single relative con-
traindications are seldom considered prohibitive, especially
if they are amenable to treatment before or after trans-
plantation. An accumulation of relative contraindications is
generally prohibitive for transplantation. Single organ fail-
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ure (respiratory insufficiency) with extracorporeal mem-
brane oxygenation (ECMO) or mechanical ventilation with
or without tracheostomy are no longer prohibitive relative
contraindications for our programme (box 2).
Donor selection criteria
As for all solid organ transplants, the demand for suitable
donor lungs exceeds the supply. The lower utilisation rates
of lungs in comparison with other solid organs are, gener-
ally, due to the fact that the lungs are more fragile and sens-
itive than other solid organs. Therefore, direct trauma to the
chest, resuscitation manoeuvres, neurogenic oedema due to
brain death, and aspiration and ventilator associated pneu-
monia lead to lower donor lung acceptance rates.
Currently accepted ideal donor criteria are given in box 3
[2]. In order to overcome the problem of donor organ short-
age, some centres use less ideal donors, so called “exten-
ded” or “marginal” donors, with similar outcomes to those
of ideal donors [3–5]. In our experience utilisation of ex-
tended donors does not compromise the outcome after lung
transplantation [6].
Operative technique
Until the year 2000 organs were preserved with Euro-
Collins solution; since then we use Perfadex® (Vitrolife,
Gothenburg, Sweden). Before an antegrade flush, 500 µg
prostaglandin E1 (Prostin VR, Upjohn, Puurs, Belgium) is
injected into the pulmonary artery in all cases. Harvesting
of the donor lungs is undertaken en bloc after perfusion.
Since 2000, we also use a retrograde flush with Perfadex®
at the time of the back-table preparation. The decision to
perform size-reduced lung transplantation is made in the
operating theatre during implantation. Peripheral segment-
al wedge resections are undertaken with a commercially
available stapler device. For lobar transplants, lobectomy is
done on the back-table. For bilateral sequential lung trans-
plants, a bilateral trans-sternal anterior thoracotomy (clam-
shell incision) or two separate anterolateral thoracotomies
(since 2000) are performed. First, the bronchial anastomos-
is is done followed by venous (atrial cuff) and pulmonary-
artery anastomoses. The recipient’s main bronchus is di-
vided one ring proximal to the upper-lobe bronchus branch.
Bronchial arteries are ligated of the peribronchial tissue
without electrocoagulation. All dissection on the bronchus
is performed using “minimal” or “no-touch” techniques in
order to keep the peribronchial tissue intact. The donor
bronchus is cut back as close as possible to the origin
of the upper lobe bronchus, with special attention to the
peribronchial tissue. Absorbable suture material polydiox-
anone (PDS, Ethicon Inc, NJ, USA) is used. A continuous
suture to the membranous wall (PDS, 4/0) and end-to-end
anastomosis with interrupted single stitches (PDS, 3/0) to
the cartilaginous part is performed [7, 8].
Postoperative management
According to our standard protocol, patients receive in-
duction therapy (antithymocyte globulin or basiliximab)
and triple immunosuppressive therapy including ciclospor-
in, azathioprine or mycophenolate mofetil (since 1997),
and prednisone. Anti-infective prophylaxis is used in ac-
cordance with our centre’s protocol, which is described
elsewhere [9, 10]. Post-transplant management at our
centre includes routine surveillance bronchoscopies with
transbronchial biopsies and bronchoalveolar lavage during
the first 6 months after transplantation, serial laboratory
lung function tests, and regular outpatient clinic follow-up
visits.
Postoperative complications
Complications following lung transplantation can occur
immediately after surgery, or days or weeks later. Clinical
suspicion and close follow-up of these patients are
strategies to reduce the morbidity and mortality in those
Box 1: Absolute contraindications to transplantation.
• Malignancy in the last 2 years. In general, a 5-year disease-free interval is prudent.
• Untreatable advanced dysfunction of another major organ system (e.g. heart, liver or kidney).
• Incurable chronic extrapulmonary infection including chronic active viral hepatitis B, hepatitis C and human immunodeficiency virus.
• Significant chest wall / spinal deformity.
• Documented nonadherence or inability to follow through with medical therapy
• Untreatable psychiatric or psychological condition associated with the inability to cooperate or comply with medical therapy.
• Substance addiction (e.g. alcohol, tobacco or narcotics) that is either active or within the last 6 months.
Adapted from Orens et al. (2006) [1]
Box 2: Relative contraindications to transplantation.
• Age older than 65 years.
• Critical or unstable clinical condition (e.g. shock, mechanical ventilation or extracorporeal membrane oxygenation).
• Severely limited functional status with poor rehabilitation potential.
• Colonisation with highly resistant or highly virulent bacteria, fungi or mycobacteria.
• Body mass index (BMI) exceeding 30 kg/m2
• Severe or symptomatic osteoporosis.
Adapted from Orens et al. (2006) [1]




PaO2 >300 mm Hg on oxygen challenge
Smoking history <20 pack years
Normal findings on bronchoscopy
Adapted from Orens et al. (2003) [2]
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who survive the procedure. The main complications after
lung transplantation can be divided into three major
groups: (1) surgical complications; (2) immunological re-
actions; and (3) side effects of immunosuppressive drugs.
Surgical complications can be classified as: (1) technical
complications; (2) pleural space complications; (3) primary
graft dysfunction; and (4) others (such as, lung hernia, in-
guinal lymphocele, phrenic nerve injury, etc.). In our series,
the overall complication rate was 38%. Tracheotomy was
performed for 19% of the recipients. We observed pleural
space complications in 24.5% of the cases. Haemothorax
requiring surgical intervention occurred in 11% of patients.
The rate of early abdominal complications requiring sur-
gical intervention was 6%.
Airway complications after lung transplantation
Refinements in lung preservation and surgical technique,
and improvements in patient selection, postoperative care
and immunosuppression have reduced the incidence of air-
way complications [11]. Reflecting these changes, the con-
temporary rate of anastomotic lesions after lung transplant-
ation has dropped from 80% before 1983 [12] to below 3%;
but a wide range of 2.6%–23.8% remains [11, 13–20].
Bronchial ischaemia is reported to be a significant risk
factor for the development of airway complications [15].
The viability of the donor bronchus is initially dependent
upon retrograde low-pressure collaterals derived from the
pulmonary artery, since bronchial arterial circulation is lost
during the harvest of the donor lungs [21].
The very low incidence of airway complications en-
countered in our programme is strong evidence in favour
of our rigorous and specific technique, which we have used
for years [7, 8]. The surgical approach for performing the
anastomosis may vary among transplant centres. Telescop-
ing, end-to-end anastomosis with a running suture for the
membranous part and interrupted sutures for the cartilagin-
Figure 1
Cut points on the donor bronchus. (a) The donor bronchus should
be cut back as close to the upper lobe bronchus origin as possible
in an oblique plane with special attention to keep peribronchial
tissues undisturbed (b) if the donor bronchus is cut at this level
there will be an risk zone for bronchial ischaemia (gray zone) (from
Weder et al. [7]).
ous part, and end-to-end anastomosis with a single running
suture are most often used [11, 15, 18, 22].
Furthermore, we are convinced that resection of the donor
bronchus down to the lobar carina in an oblique plane
(fig. 1), in conjunction with keeping the peribronchial tis-
sue intact, is a critical step when performing the bronchial
anastomosis. The often cited disadvantages of a single-
stitch technique compared with a running suture – more
time required, a higher load of foreign tissue due to the
need to tie multiple knots and an overall increased tissue ir-
ritation – are not reflected in our experience [7].
Currently, in over 650 anastomoses performed at our insti-
tution, no significant dehiscence was observed. An airway
complication is defined as any bronchial anastomotic com-
plication that becomes symptomatic owing to airflow lim-
itation, bleeding or a fistula, and that may require an in-
tervention, either endobronchially or as an open revision.
In one patient, a small fistula was detected and closed sur-
gically on postoperative day five. In a previous analysis,
in only 4.9% (10/206) of recipients was luminal narrowing
found at the first surveillance bronchoscopy in a consec-
utive series of 391 bronchial anastomoses (narrowing was
found in 18/391 [4.6%] anastomoses). This rate decreased
to 2.3% (9/391) after 6 months. None of these patients re-
quired any intervention, and there was no death related
to bronchial anastomotic complications [7]. We know that
bronchial anastomotic complications can be avoided by use
of a standardised surgical technique that respects the fact
that the donor bronchus is poorly vascularised. Prevention
of fungal infections with aggressive antifungal treatment
may play an important additional role [7].
Outcomes
From November 1992 to December 2011, a total of 342
lung transplantations were performed at the Zurich
University Hospital. Bilateral lung transplants were per-
formed in 308 patients, single lung transplants in 33 and a
heart-lung transplant in 1. The number of transplantations
performed in each calendar year are shown in figure 2. The
number of retransplantations was 14. The censor date for
all survival data is 15th November 2012. Retransplanta-
tions (n = 14) and heart-lung transplantation (n = 1) were
excluded from the survival analyses. Overall survival rates
at 1, 3 and 5 years were 84%, 71% and 66.5%, respectively
(fig. 3). The 29th annual report of the ISHLT (2012) stated
Figure 2
The number of lung transplantations performed each year.
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that 39,835 adult lung transplantations were performed up
to June 2011 [23]. In this report the survival rate was 79%
Figure 3
Overall survival of patients who underwent lung transplantation at
the Zurich University Hospital. Censor date for all survival data is
15 November 2012. Retransplantation (n = 14) and heart-lung
transplantation (n = 1) were excluded.
Figure 4
Kaplan-Meier survival curve showing a significantly better outcome
in patients who underwent bilateral versus unilateral lung
transplantation (p = 0.0001, log-rank test).
Figure 5
Kaplan-Meier survival curve comparing two different eras (p = 0.02,
log-rank test).
at 1 year, 64 % at 3 years and 53% at 5 years. The Japanese
Lung transplantation report of 2012 recorded 86% survival
at 1 year, 79% at 3 years and 73% at 5 years [24]. Kreisel
et al from Washington University, St Louis, reported 84%
1-year survival and 56% at 5 years in 1,000 patients who
underwent lung transplantation [25].
Type of the procedure: unilateral versus bilateral lung
transplant
Overall survival rates at 1, 3 and 5 years for recipients un-
dergoing bilateral lung transplantation were 86%, 74% and
68%, respectively, and for unilateral lung transplantation
were 61.5%, 49% and 49%, respectively (p = 0.0001, log-
rank test; fig. 4). In our programme, the number of unilat-
eral lung transplantations has significantly decreased over
the years. Between 1992 and 1997, 36% of the transplants
were unilateral; this decreased to 3% in the period between
2006 and 2011.
Era effect
We performed 87 lung transplants (1 retransplant was ex-
cluded) between 1992 and 1999 with 1-, 3- and 5-year sur-
vival rates of 76%, 63% and 60%, respectively. Between
the year 2000 and the end of 2011, 240 transplants were
performed with survival rates of 87%, 75% and 69%, re-
spectively (p = 0.02, log-rank test; fig. 5) (14 retransplants
and 1 heart-lung transplant were excluded). In the second
era we increased the number of transplants performed in
our centre. The improved survival rates are due to better
lung preservation, and improvements in intensive care
management, immunosuppressive treatment, antibiotic and
anti-fungal treatments, as well as continued long-term
follow-up by transplant pulmonologists.
Effect of underlying diagnosis on survival
Cystic fibrosis
In our transplant programme, cystic fibrosis (CF) was the
most common indication, accounting for 35% of all lung
transplants performed. According to the recent ISHLT re-
gistry data, CF constitutes the third most common indica-
tion for lung transplantation at a global level [23]. Ultim-
ately, it is the only treatment option that can allow patients
Figure 6
Survival by diagnosis since 2000 (p = 0.1, log-rank test).
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with advanced CF lung disease to obtain normal respirat-
ory health [26]. Good post-transplant outcome for CF has
been reported from transplant centres worldwide [26–28].
Despite transplant-related and medical comorbidities, pro-
longed survival and good quality of life have been reported
for CF recipients [28–32].
Although single-centre reports indicate increased mortality
rates in patients with Burkholderia cepacia complex, espe-
cially Burkholderia cepecia genomovar III, in Zurich we
do not systematically exclude these patients from trans-
plantation [33–35].
In our series, we transplanted two recipients with Burk-
holderia cepacia complex. One of them died of bronchi-
olitis obliterans syndrome (BOS) 5 years after transplanta-
tion. The other patient is clinically stable and BOS-free at
9 years post-transplant.
The survival rates for patients undergoing lung transplanta-
tion for CF (n = 107) in Zurich were 86%, 74% and 70% at
1, 3 and 5 years, respectively. Survival rates for this group
of patients since 2000 were 89%, 78% and 74.1% at 1, 3
and 5 years, respectively (fig. 6).
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is the most
common indication for which lung transplantation is per-
formed [23]. Referral for transplantation in COPD patients
should be considered only for patients who continue to de-
teriorate despite optimal medical and surgical therapy, in-
cluding smoking cessation, maximal bronchodilator treat-
ment, rehabilitation, long-term oxygen therapy, and endo-
scopic or surgical lung volume reduction where feasible.
The definition of the appropriate timing for transplantation
is complicated because very symptomatic COPD patients
may have a relatively good prognosis. Therefore, the ques-
tion of whether it may be justified to perform a transplant
primarily for quality-of-life reasons arises frequently in
these patients [1].
Listing criteria for COPD patients are: body-mass index,
airflow obstruction, dyspnoea and exercise capa-
city(BODE) index of 7 to 10, or at least one of the follow-
ing: history of hospitalisation for exacerbation associated
with acute hypercapnia (PCO2 exceeding 50 mmHg), pul-
monary hypertension, forced expiratory lung volume in 1
second (FEV1) less than 20% of predicted, and either dif-
fusing capacity of the lung for carbon monoxide (DLCO)
less than 20% of predicted or homogenous distribution of
emphysema [1, 36].
In our clinic we performed 86 lung transplantations for
COPD. One-, 3- and 5-year survival rates were 85%, 76%
and 71%, respectively. Survival rates for COPD patients
since 2000 were 86%, 77% and 74.7% at 1, 3 and 5 years,
respectively (fig. 6). Similar survival rates were also repor-
ted from the St. Louis Lung Transplant Program [37]. They
reported 88.6% 1-year, 75.6% 3-year and 70.4% 5-year
survival rates in 140 recipients transplanted between1995
and 2000.
Idiopathic pulmonary fibrosis
Worldwide, idiopathic pulmonary fibrosis (IPF) patients
have the worst prognosis of all patients undergoing lung
transplantation [23]. In addition, IPF patients have the
highest mortality rates on the waiting list [23]. Early refer-
ral of these patients is very important to reduce pretrans-
plant and perioperative mortality.
Survival for 65 patients transplanted for IPF was 83%,
65.9% and 54.5% at 1, 3 and 5 years, respectively. Since
the year 2000, 1-, 3- and 5- year survival rates were 86.8%,
67.3% and 50.4%, respectively (fig. 6). The recent ISHLT
Registry reported 74% 1-year, 58% 3-year and 46% 5-year
survival rates for IPF recipients [23].
Primary pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive
and severely disabling disorder induced by an increase
in pulmonary vascular resistance and ultimately leading
to right heart failure and death [1]. For these patients,
severe dyspnoea on exertion, of New York Heart Asso-
ciation (NYHA) class III or IV (which reflects severely
limited daily activities), is the referral criterion. Persistent
NYHA class III or IV dyspnoea on medical treatment, fail-
ure to respond to intravenous medical treatment, mean pul-
monary artery pressure (mPAP) >50 mm Hg, cardiac index
<2 l/min/m2, and right atrial pressure >15 mm Hg are cri-
teria for transplantation [1].
The survival rates for patients undergoing lung transplanta-
tion for primary pulmonary arterial hypertension (PPH) (n
= 22) were 63.6%, 54.2% and 48.8% at 1, 3 and 5 years,
respectively. Since the year 2000, 1-, 3- and 5-year surviv-
al rates were 81%, 68% and 60.6%, respectively (fig. 6).
The recent ISHLT Registry reported 69.8% 1-year, 58.8%
3-year and 50.2% 5-year survival for PPH recipients [23].
Special considerations
Perioperative extracorporeal membrane oxygenation
implementation
Extracorporeal membrane oxygenation (ECMO) is cur-
rently used in lung transplantation either to bridge patients
prior to transplantation or to treat post-transplant severe
primary graft dysfunction [38].
In our programme we have steadily increased the number
of transplantations performed with ECMO support. We
transplanted 128 patients (39%) with ECMO support or
cardiopulmonary bypass. Since 2000 we have preferred
using ECMO rather than cardiopulmonary bypass during
Figure 7
The number of patients who underwent lung transplantation
exclusively under extracorporeal membrane oxygenation support
since 2000 at our centre.
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lung transplantation. Figure 7 shows patients transplanted
with ECMO support since 2000. In 11 of these ECMO
was used as a bridging procedure. The decision to perform
the operation with ECMO is made according to preop-
eratively diagnosed pulmonary arterial hypertension, gas
exchange status including one-lung ventilation, temporary
clamping of the ipsilateral pulmonary artery, and/or after
transplantation of one side in the case of graft dysfunction.
If graft dysfunction occurs immediately after reperfusion in
the operating room or the recipient has preoperatively dia-
gnosed severe pulmonary arterial hypertension we contin-
ue ECMO support for a couple of days on the ICU. For
venoarterial (VA) cannulation, we prefer a femoral vein
and the ascending aorta or a femoral artery. If we know that
we will continue the ECMO support in the postoperative
period we use a subclavian artery or contralateral femoral
artery, connecting the cannula with a vascular graft. Hepar-
in is administered as 50 IU/kg at the time of ECMO im-
plantation and then titrated to maintain an activated clotting
time of 150–180 seconds.
ECMO as a bride to lung transplantation is increasingly
used worldwide. Recently, Hoopes et al. reported 93%
1-year and 66% 5-year survival rates comparable to those
transplanted without ECMO as a bridging procedure [39].
In our series we had 11 patients bridged to transplantation
on ECMO. Our 1-year and 2-year survival rates were 64%
and 45%, respectively.
Size-reduced lung transplantation
For transplant recipients requiring bilateral lung transplant-
ation, the donor-to-recipient supply and demand mismatch
is even greater [40]. Owing to the increasing scarcity of
donors, in particular for smaller recipients, advanced oper-
ative strategies have been developed [41–46]. Size-reduced
lung transplantation is increasingly performed, often in ur-
gent cases. Peripheral segmental resection is the most com-
mon method for downsizing, whereas lobar and split-lung
transplants are other options performed [41–46].
Whenever size-reduced lung transplantation is undertaken,
appropriate size-matching of donor organs and the recip-
ient is vital. Oversized lung grafts can potentially lead to
atelectasis and impaired airway clearance due bronchial
anatomy distortion. Undersized grafts cause lung hyperex-
pansion and might limit exercise tolerance as a result of
haemodynamic compromise. Recently we have shown that,
in size-reduced lung transplantation, the recipient’s best
postoperative FEV1 could be predicted from the donor’s
calculated and corrected FEV1, adjusted for the number of
transplanted segments. Moreover, our data demonstrated
that size-reduced lung transplantation can be performed
safely with peri- and post-operative complications and
post-transplant outcome comparable to standard lung trans-
plantation [47, 48].
Lobar lung transplantation
The limitation of lung transplantation due to size-mis-
match, especially in smaller adults and paediatric recipi-
ents, could be overcome by utilising lobar lung transplant-
ation. Since January 2000, 75 recipients received down-
sized lungs. Of these, 23 patients underwent bilateral lobar
lung transplantation (BLLT) with anatomic lobectomy (9%
of the total lung transplantations in this period) [49]. Indic-
ations for BLLT were cystic fibrosis (n = 10), pulmonary
fibrosis (n = 8), emphysema (n = 3), and primary pulmon-
ary hypertension, progressive systemic sclerosis and bron-
chiolitis (for each n = 1). Sixteen patients were female, with
a median age of 41 years (range 13‒66 years). The decision
to perform size-reduced lung transplantation was made in
the operating theatre during implantation on the basis of
visual assessment of the size discrepancy. Our data demon-
strated that bilateral lobar lung transplantation has short-
and long-term outcomes comparable to standard bilateral
lung transplantation.
Donation after cardiac death (DCD) programme
One of the solutions for lack of suitable donor lungs is to
use donation after cardiac death (DCD) donors. Mid- and
long-term results from DCD donors are encouraging, with
survival rates comparable to those from brain death donors
[50–53]. Recently, Levvey et al. from Australia reported an
excellent 5-year survival rate of 90% from their cohort of
72 patients [51].
Zurich University Hospital started a DCD programme from
category 3 donors in October 2011. Since 2012, we have
performed three DCD lung transplantations, which are not
included in this paper.
Future directions
Ex-vivo lung perfusion
Ex-vivo lung perfusion (EVLP) was proposed originally
to assess the function of the lung donated after a cardiac
death , as an interim evaluation of the graft prior to trans-
plantation [54, 55]. The concept of EVLP is not only to
evaluate lungs before transplantation, but also to recondi-
tion lungs of inferior quality outside the cadaver and to ex-
tend the cold ischaemic time by intermittent warm reper-
fusion [56]. Similar early outcomes have been reported in
recipients who underwent transplantation after EVLP to
those with conventionally selected and transplanted lungs
[56–59]. Based on our extensive research in this field in the
last 7 years we also have started an EVLP programme in
our transplant centre [60–63]. We performed EVLP in two
marginal donors. These lungs did not fulfil the implantation
criteria and were not transplanted.
Lung engineering
Advances in stem-cell and tissue engineering research res-
ulted recently in the creation of a bioartificial lung, which
was able to maintain gas exchange at room air after in-vivo
transplantation [64].
The donor lungs were decellularised with detergent perfu-
sion and yielded scaffolds with acellular vasculature, air-
ways and alveoli. To regenerate gas exchange tissue, scaf-
folds were seeded with epithelial and endothelial cells.
To establish function, cell-seeded constructs were perfused
and ventilated in a bioreactor simulating the physiologic
environment of developing lungs. By day 5, constructs
could be perfused with blood and ventilated at physiologic-
al pressures, generating gas exchange comparable to that
of isolated native lungs. To show in-vivo function, regen-
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erated lungs were transplanted into the orthotopic position
in an animal model. After transplantation, constructs were
perfused by the recipient's circulation and ventilated by
means of the recipient’s airway and respiratory muscles,
providing gas exchange in vivo for up to 6 hours after ex-
tubation [63].
Conclusion
The additional improvement in post-transplant survival of
lung transplant recipients in the recent era at our centre
is most likely due to a number of factors: better surgical
techniques, organ preservation and intensive-care manage-
ment probably played a role. In addition, careful post-trans-
plant long-term management by transplant pulmonologists,
including rigorous treatment of airway infections, sinus
surgery and routine nasal care (CF recipients), long-term
therapy with macrolide antibiotics for (BOS), and extracor-
poreal photopheresis in selected recipients with BOS and
recurrent acute allograft rejection might have contributed
to improved outcomes at our centre as well [27, 32].
The two main problems are limited organ supply and fail-
ure to ensure long-term allograft function with the current
immunosuppression strategies. Increased use of DCD
donors, utilisation of EVLP to assess and recondition mar-
ginal donor organs, and advances in tissue engineering re-
search could overcome at least the limited supply of eli-
gible donor lungs for transplantation.
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Figures (large format)
Figure 1
Cut points on the donor bronchus. (a) The donor bronchus should be cut back as close to the upper lobe bronchus origin as possible in an
oblique plane with special attention to keep peribronchial tissues undisturbed (b) if the donor bronchus is cut at this level there will be an risk
zone for bronchial ischaemia (gray zone) (from Weder et al. [7]).
Figure 2
The number of lung transplantations performed each year.
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Figure 3
Overall survival of patients who underwent lung transplantation at the Zurich University Hospital. Censor date for all survival data is 15
November 2012. Retransplantation (n = 14) and heart-lung transplantation (n = 1) were excluded.
Figure 4
Kaplan-Meier survival curve showing a significantly better outcome in patients who underwent bilateral versus unilateral lung transplantation (p
= 0.0001, log-rank test).
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Figure 5
Kaplan-Meier survival curve comparing two different eras (p = 0.02, log-rank test).
Figure 6
Survival by diagnosis since 2000 (p = 0.1, log-rank test).
CF = cystic fibrosis; COPD = chronic obstructive pulmonary disease; IPF = idiopathic pulmonary fibrosis; PPH = primary pulmonary arterial
hypertension.
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Figure 7
The number of patients who underwent lung transplantation exclusively under extracorporeal membrane oxygenation support since 2000 at our
centre.
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